12:00 AM
May 21, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Promethera HepaStem: Phase I/II started

Promethera began an open-label, European Phase I/II trial to evaluate Promethera HepaStem in patients with Crigler-Najjar syndrome or urea cycle diseases. The product has Orphan Drug designation...

Read the full 115 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >